Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412 - PubMed (original) (raw)
. 2007 Apr 1;109(7):3031-41.
doi: 10.1182/blood-2006-07-032714.
Matthias Mayerhofer, Karoline V Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F Pickl, Volker Wacheck, Edgar Selzer, Leonhard Müllauer, Hermine Agis, Christian Sillaber, Peter Valent
Affiliations
- PMID: 17110460
- DOI: 10.1182/blood-2006-07-032714
Free article
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412
Karl J Aichberger et al. Blood. 2007.
Free article
Abstract
MCL-1 is a Bcl-2 family member that has been described as antiapoptotic in various myeloid neoplasms. Therefore, MCL-1 has been suggested as a potential new therapeutic target. Systemic mastocytosis (SM) is a myeloid neoplasm involving mast cells (MCs) and their progenitors. In the present study, we examined the expression and functional role of MCL-1 in neoplastic MCs and sought to determine whether MCL-1 could serve as a target in SM. As assessed by RT-PCR and immunohistochemical examination, primary neoplastic MCs expressed MCL-1 mRNA and the MCL-1 protein in all SM patients examined. Moreover, MCL-1 was detectable in both subclones of the MC line HMC-1--HMC-1.1 cells, which lack the SM-related KIT mutation D816V, and HMC-1.2 cells, which carry KIT D816V. Exposure of HMC-1.1 cells or HMC-1.2 cells to MCL-1-specific antisense oligonucleotides (ASOs) or MCL-1-specific siRNA resulted in reduced survival and increased apoptosis compared with untreated cells. Moreover, MCL-1 ASOs were found to cooperate with various tyrosine kinase inhibitors in producing growth inhibition in neoplastic MCs, with synergistic effects observed with PKC412, AMN107, and imatinib in HMC-1.1 cells and with PKC412 in HMC-1.2 cells. Together, these data show that MCL-1 is a novel survival factor and an attractive target in neoplastic MCs.
Similar articles
- PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, Gruze A, Samorapoompichit P, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Blood. 2006 Jan 15;107(2):752-9. doi: 10.1182/blood-2005-07-3022. Epub 2005 Sep 27. Blood. 2006. PMID: 16189265 - Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P. Gleixner KV, et al. Haematologica. 2007 Nov;92(11):1451-9. doi: 10.3324/haematol.11339. Haematologica. 2007. PMID: 18024392 - Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P. Aichberger KJ, et al. Blood. 2009 Dec 17;114(26):5342-51. doi: 10.1182/blood-2008-08-175190. Epub 2009 Oct 22. Blood. 2009. PMID: 19850739 - Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C, DeRemer DL, Akin C. Ustun C, et al. Leuk Res. 2011 Sep;35(9):1143-52. doi: 10.1016/j.leukres.2011.05.006. Epub 2011 Jun 8. Leuk Res. 2011. PMID: 21641642 Review. - Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A. Pardanani A. Am J Hematol. 2019 Mar;94(3):363-377. doi: 10.1002/ajh.25371. Epub 2019 Jan 2. Am J Hematol. 2019. PMID: 30536695 Review.
Cited by
- CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
Bandara G, Falduto GH, Luker A, Bai Y, Pfeiffer A, Lack J, Metcalfe DD, Olivera A. Bandara G, et al. Front Immunol. 2023 Mar 21;14:1078958. doi: 10.3389/fimmu.2023.1078958. eCollection 2023. Front Immunol. 2023. PMID: 37025992 Free PMC article. - A Critical Function for the Transcription Factors GLI1 and GLI2 in the Proliferation and Survival of Human Mast Cells.
Falduto GH, Pfeiffer A, Zhang Q, Yin Y, Metcalfe DD, Olivera A. Falduto GH, et al. Front Immunol. 2022 Feb 16;13:841045. doi: 10.3389/fimmu.2022.841045. eCollection 2022. Front Immunol. 2022. PMID: 35251038 Free PMC article. - Precision Medicine in Systemic Mastocytosis.
Nicolosi M, Patriarca A, Andorno A, Mahmoud AM, Gennari A, Boldorini R, Gaidano G, Crisà E. Nicolosi M, et al. Medicina (Kaunas). 2021 Oct 20;57(11):1135. doi: 10.3390/medicina57111135. Medicina (Kaunas). 2021. PMID: 34833353 Free PMC article. Review. - Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Monaldi C, De Santis S, Mancini M, Bruno S, Cavo M, Soverini S. Monaldi C, et al. Mediterr J Hematol Infect Dis. 2021 Jul 1;13(1):e2021046. doi: 10.4084/MJHID.2021.046. eCollection 2021. Mediterr J Hematol Infect Dis. 2021. PMID: 34276915 Free PMC article. Review. - Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B, Arock M, Lyons JJ, Bachelot G, Schwartz LB, Reiter A, Jawhar M, Schwaab J, Lange M, Greiner G, Hoermann G, Niedoszytko M, Metcalfe DD, Valent P. Nedoszytko B, et al. Int J Mol Sci. 2021 Jan 2;22(1):411. doi: 10.3390/ijms22010411. Int J Mol Sci. 2021. PMID: 33401724 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials